Zenas BioPharma

ZBIO

Market cap $1.13B

The big banks have started off the new earnings-reporting season, which means that insider buying of stocks could be muted for a while.

Leon O. Moulder, the founder, Chief Executive Officer, and Chairman of the Board of Directors, acquired 36,928 shares of Zenas BioPharma (ZBIO -7.97%) on October 7, 2025, through an open-market purchase, as disclosed in the SEC Form 4 filing.

Zenas BioPharma (ZBIO) secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications. ZBIO's two late-stage candidates, obexelimab and orelabrutinib, drive optimism, with topline Phase 3 INDIGO trial data for obexelimab expected in late 2025. Strong cash position and recent private placement provide operational runway through 4Q26, supporting ongoing clinical development and mitigating dilution risks.

Zenas BioPharma said on Wednesday it has secured global rights to develop and commercialize an experimental drug from China-based InnoCare Pharma for multiple sclerosis and other autoimmune conditions under a licensing deal potentially worth more than $2 billion.

- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis (MS) -

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease - WALTHAM, Mass. and New York, Sept.

WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for autoimmune diseases, today announced management's presentations at the following investor conferences in September:

- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -

Zenas BioPharma, Inc.'s Obexelimab offers a differentiated, non-depleting B-cell inhibition approach, with promising Phase 2 data in IgG4 and upcoming pivotal catalysts in 2025. The lead asset's blockbuster potential hinges on positive Phase 3 IgG4 results, with analysts projecting peak sales over $1.5bn if approved. ZBIO risks include obexelimab's prior Phase 2 failure in lupus nephritis and limited pipeline depth, but strong cash reserves support near-term operations.

WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase 112,000 shares of the Company's common stock to a newly hired employee of the Company as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).